MLTX logo

MLTX
MoonLake Immunotherapeutics

5,780
Mkt Cap
$1.24B
Volume
479,019.00
52W High
$62.75
52W Low
$5.95
PE Ratio
-4.91
MLTX Fundamentals
Price
$17.32
Prev Close
$17.75
Open
$17.68
50D MA
$16.88
Beta
0.59
Avg. Volume
1.42M
EPS (Annual)
-$3.53
P/B
4.06
Rev/Employee
$0.00
$531.37
Loading...
Loading...
News
all
press releases
This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday
Top Wall Street analysts upgraded APA Corp. & MoonLake Immunotherapeutics, see why & what other analysts think on our analyst ratings page.read more...
Benzinga·5d ago
News Placeholder
More News
News Placeholder
Wolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform"
Wolfe Research upgraded shares of MoonLake Immunotherapeutics from an "underperform" rating to an "outperform" rating and set a $24.00 target price for the company in a report on Monday...
MarketBeat·5d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade...
MarketBeat·9d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Rothschild & Co Redburn to Buy Rating
Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and set a $40.00 price target on the stock in a report on Thursday...
MarketBeat·9d ago
News Placeholder
Caitong International Asset Management Co. Ltd Increases Holdings in MoonLake Immunotherapeutics $MLTX
Caitong International Asset Management Co. Ltd increased its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 22,387.5% in the third quarter, according to its most recent 13F...
MarketBeat·10d ago
News Placeholder
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
Key PointsCormorant Asset Management increased its MoonLake Immunotherapeutics position by 2,361,260 shares in the fourth quarter; the estimated trade value is $27.86 million based on average...
Nasdaq News: Markets·12d ago
News Placeholder
Boxer Capital Management LLC Acquires New Holdings in MoonLake Immunotherapeutics $MLTX
Boxer Capital Management LLC bought a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 3rd quarter, according to its most recent filing with the Securities...
MarketBeat·13d ago
News Placeholder
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
Avoro Capital Advisors LLC lessened its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 51.8% in the 3rd quarter, according to the company in its most recent 13F...
MarketBeat·14d ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the sixteen analysts that are presently covering the firm, MarketBeat Ratings...
MarketBeat·15d ago
News Placeholder
TD Asset Management Inc Lowers Holdings in MoonLake Immunotherapeutics $MLTX
TD Asset Management Inc lowered its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 42.7% in the third quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·21d ago
<
1
2
...
>

Latest MLTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.